GlobeNewswire by notified

Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-position

Share
  • Total revenue of CHF 148 million exceeding 2021 financial guidance, driven by 65% increase in non-deferred revenue contributions from Cresemba and Zevtera
  • CHF 150 million year-end cash and financial investments above 2021 financial guidance

Ad hoc announcement pursuant to Art. 53 LR

Basel, January 10, 2022

Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced today the unaudited preliminary revenue and year-end cash-position for the financial year 2021. Total revenue, non-deferred revenue contributions from Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) and year-end cash and financial investments are all above guidance.

Non-deferred revenue contributions from Basilea’s marketed products, the antifungal Cresemba and the antibiotic Zevtera, are expected to have increased by 65% to approximately CHF 129 million (FY 2020: CHF 78.2 million). Total revenue, including revenue contributions from Cresemba and Zevtera as well as BARDA reimbursements, offsetting ceftobiprole phase 3 development expenses and other revenue contributions, is expected to amount to approximately CHF 148 million (FY 2020: CHF 127.6 million). Basilea also reported preliminary CHF 150 million cash and financial investments at year-end 2021 or CHF 173 million, excluding the impact from the reduction of outstanding convertible bonds.

At half-year reporting 2021, Basilea had guided for non-deferred revenue contributions from Cresemba and Zevtera of CHF 115 – 125 million, total revenue of CHF 134 – 144 million and a year-end cash position of CHF 142 – 147 million (CHF 165 – 170 million, excluding the impact from the reduction of convertible bonds in FY 2021).

David Veitch, Chief Executive Officer, commented: “We are very pleased with the significantly increased non-deferred revenue contributions from Cresemba and Zevtera, which are reflecting the continued progress that we, together with our partners, are making in the commercialization of our brands. Global in-market sales of Cresemba have exceeded 300 million US dollars in the 12 months to the end of September 2021. The continued commercial success of Cresemba, as well as the progress made in making Cresemba available in Japan and China have triggered several sales, development and regulatory milestone payments to Basilea throughout 2021.”

Adesh Kaul, Chief Financial Officer, added: “The impressive growth in our Cresemba and Zevtera non-deferred revenue is indicative of the robust global in-market performance of our brands and the continued regulatory progress made by our partners with regard to accessing new markets. We are looking forward to the key milestones for our anti-infectives franchise in 2022, including anticipated regulatory decisions for Cresemba in China and Japan and the results of our phase 3 ERADICATE study with ceftobiprole. Positive outcomes for these key milestones could have a significant positive mid-term impact on our commercial anti-infectives business. Our strong year-end cash position and the reduction of the outstanding convertible bonds provide us with the required financial flexibility to execute on our strategic priorities.”

The audited full financial statements as well as the annual report 2021 will be published on February 15, 2022. The final audited revenue for 2021 and the cash position as of year-end 2021 may differ from the preliminary reported numbers.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with cancer and infectious diseases. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have several preclinical assets in both cancer and infectious diseases in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Phone +41 61 606 1102
E-mail media_relations@basilea.com
investor_relations@basilea.com

This ad hoc announcement can be downloaded from www.basilea.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Nordic American Tankers Ltd (NYSE: NAT) – Further Purchase of NAT shares by Board Member Alexander Hansson21.1.2022 16:32:14 CET | Press release

Friday, January 21, 2022 Dear Shareholders and Investors, Alexander Hansson, Board Member in Nordic American Tankers Ltd (NAT) and son of Herbjorn Hansson, the NAT Founder, Chairman and CEO, has today bought 50,000 shares in NAT at $ 1.557 per share. Following the transaction, Alexander Hansson privately owns 1,185,000 shares in NAT. As in the past, the Hansson family is the largest private shareholder in the company. Alexander Hansson commented: "I strongly believe in the future of NAT" Sincerely, Herbjorn Hansson Founder, Chairman & CEO Nordic American Tankers Ltd. www.nat.bm CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, obje

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK TREASURY BILLS21.1.2022 16:20:00 CET | Press release

Bid procedure, 2022-01-26BillsSWEDISH T-BILL: SE0017232689. 2022-04-20 Bid date2022-01-26Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SE0017232689: 2000 mln SEK +/-1000 mln SEK Highest permitted bid volume (corresponding nominal amount)SE0017232689: 2000 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2022-01-28Delivery of billsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2022-01-21 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS21.1.2022 16:20:00 CET | Press release

Bid procedure, 2022-01-25BondsKOMMUNINVEST I SVERIGE: 2311. SE0010948240. 2023-11-13 KOMMUNINVEST I SVERIGE: 2611, SE0012569572, 2026-11-12 KOMMUNINVEST I SVERIGE: 2805, SE0015660139, 2028-05-12 BidsBids on interest and volume are entered via Bloomberg Bond Auction SystemBid date2022-01-25Bid times10.00-11.00Requested volume (corresponding nominal amount)2311: 500 mln SEK +/-250 mln SEK 2611: 500 mln SEK +/-250 mln SEK 2805: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)2311: 500 mln SEK per bid 2611: 500 mln SEK per bid 2805: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2022-01-27Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383General Terms and ConditionsGeneral Terms and Conditions General Terms and Conditions för the Riksbank’s Purchase

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS21.1.2022 16:20:00 CET | Press release

Bid procedure, 2022-01-28BondsSWEDEN I/L BOND: 3109. SE0005703550. 2025-06-01 SWEDEN I/L BOND: 3114, SE0013748258, 2030-06-01 Bid date2022-01-28Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3109: 500 mln SEK +/-250 mln SEK 3114: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)3109: 500 mln SEK per bid 3114: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2022-02-01Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2022-01-21 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be

Avance Gas Holding Ltd - Enter into Time Charter Agreement for Avance Capella21.1.2022 14:33:03 CET | Press release

Bermuda, 21 January 2022 - Avance Gas Holding Ltd ("AGAS" or the "Company") announce that we have entered into a Time Charter Agreement for a period of 2 years for our second dual fuel VLGC, Avance Capella, to LPG & Ethylene Shipowner and LPG trader, Petredec. The vessel will commence the time charter shortly after delivery ex-yard in South Korea end of February 2022 and the time charter hire has a mechanism which gives both parties exposure to the spot market rate. This transaction is another step in executing on our strategy to increase our time charter portfolio while also maintaining access to the market upside. For further queries, please contact: Kristian Sørensen, CEO Tel: +47 22 00 48 00 Randi Navdal Bekkelund, CFO Tel: +47 22 00 48 00 About Avance Gas: Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carrier (VLGC) and operates a fleet of thirteen ships

Proposals by the Nomination Board to the Annual General Meeting 2022 of Suominen21.1.2022 13:00:00 CET | Press release

Suominen Corporation's stock exchange release on January 21, 2022 at 2:00 p.m. EET Proposal on the number of the members, on the composition, and on the Chair of the Board of Directors The Nomination Board of Suominen Corporation’s shareholders proposes to the Annual General Meeting that the number of Board members remains unchanged and would be six (6). The Nomination Board proposes to the Annual General Meeting that Andreas Ahlström, Björn Borgman, Jaakko Eskola, Nina Linander and Laura Raitio would be re-elected as members of Suominen Corporation’s Board of Directors. Out of the current Board members, Sari Pajari-Sederholm has informed that she is not available as a candidate for the Board of Directors. In addition, the Nomination Board proposes that Aaron Barsness would be elected as a new member of the Board of Directors. Mr. Aaron Barsness (born 1973, BA (Biology and Environmental Studies), U.S. and Swedish citizen) currently works as the CMO of Fazer Group. He has held a number

Auriant Mining AB (publ.) publishes 12m 2021 operational update21.1.2022 11:20:00 CET | Press release

Highlights: In 12m 2021, total gold production amounted to 910.8 kg (29,283 oz), compared to 964.7 kg (31,014 oz) in 12m 2020, a decrease of 6%, or 53.9 kg (1,731 oz), but in line with the 2021 production plan; Hard rock gold production was 893.3 kg (28,720 oz), compared to 952.7 kg (30,629 oz) in 12m 2020, a decrease of 6%, or 59.4 kg (1,909 oz);Alluvial gold production amounted to 17.5 kg (563 oz), compared to 12.0 kg (386 oz) in 2020, an increase of 46%, or 5,5 kg (178 oz);12m 2021, total gold sales were 818.5 kg (26,316 oz), compared to 946.4 kg (30,428 oz) in 12m 2020, a decrease of 127.9 kg (4,112 oz), or 14%;428,300 tonnes of ore were processed with an average grade of 2.30 g/t;In 12m of 2021, the CIL plant operated for 8,004 hours at an increased throughput rate of 53.5 tonnes per working hour (>50 t/hour) and at the targeted recovery rate of 91.2%;458,500 tonnes of ore were mined in 12m 2021, compared to 387,200 tonnes in 12m 2020, an increase of 71,300 tonnes or 18%. Strippin